Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice

Bone Marrow Transplantation

Volumn 27, Issue 3, 2001, Pages 279-285

  Zeis, M ^a   Steinmann, J ^a   Petrela, E ^a   Hartung, G ^b   Schmitz, N ^a   Uharek, L ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Donor vaccination; Graft versus myeloma effects; Idiotypic protein

Indexed keywords

CD8 ANTIGEN; FREUND ADJUVANT; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G2A; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; OKT 3;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CELL SECRETION; CELL TRANSFER; CONTROLLED STUDY; DEATH; DONOR; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNIZATION; IN VITRO STUDY; LETHAL DOSE; LONG TERM CARE; MOUSE; MOUSE STRAIN; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME; T LYMPHOCYTE; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; IMMUNOGLOBULIN IDIOTYPES; IMMUNOGLOBULINS; INJECTIONS; LYMPHOCYTE TRANSFUSION; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MULTIPLE MYELOMA; MYELOMA PROTEINS; SPLEEN; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0035112623     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702785     Document Type: Article

References (28)

1. Multiple myeloma
2. Autologous and allogeneic transplants for multiple myeloma
3. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European group for blood and marrow transplantation
4. A molecular and clinical remission in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells
5. Graft-versus-leukemia effect: No longer an epiphenomenon
6. Donor leukocyte transfusion for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
7. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
8. Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantation
9. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
10. Adoptive T-cell therapy
11. Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation
12. Graft-versus-myeloma effect in two cases
13. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: Impact of infused and residual donor T cells
14. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins
15. Myeloma proteins as tumor-specific transplantation antigens
16. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: A strategy for using autologous marrow as an anti-tumor therapy
17. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor
18. Induction of immune responses in patients with B-cell lymphoma against the surface-immunglobluin idiotype expressed by their tumors
19. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
20. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma
21. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony stimulating factor against lymphoma
22. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor
23. Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: A strategy for enhancing the specific antitumor effect of marrow grafts
24. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation
25. Vaccine induced graft-versus-tumor effects are separable from graft-versus-host disease
26. + T cells confer idiotype-specific tumor resistance in the absence of antibodies
27. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T cell responses
28. Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma